UNLABELLED: In about 10% cases of Duchenne muscular dystrophy (DMD), death is due to cardiac dysfunction. The recognition of cardiomyopathy in DMD is thus important. OBJECTIVE: To assess cardiac involvement in DMD patients by clinical, radiographic, electrocardiographic (ECG) and echocardiographic monitoring and correlate clinical parameters, CPK levels, presence of gene deletion and steroid therapy with cardiac involvement. METHODS: Thirty patients beyond 6 years age, with DMD in advanced stage disease/non-ambulatory were recalled. A detailed clinical evaluation, CPK levels, gene deletion studies were carried out. Cardiac investigations included Chest X-ray, 12 lead ECG and echocardiography. RESULTS: Nineteen patients were non-ambulatory at the time of enrollment. Symptoms or signs suggestive of cardiac dysfunction were seen in only 10%. Gene deletion was identified in 70.3%. Around one-third patients had cardiomegaly. ECG abnormalities were present in 93.3% patients and commonest abnormality was R > 4 mm in V1. Ejection fraction (EF) < 55% was observed in 64.2% and EF < 50% in 17.8%. CONCLUSION: Cardiomyopathy of DMD is characterized by lack of symptoms and few physical signs. Presence of subtle changes like sinus tachycardia may suggest early cardiac involvement. Thus echocardiography is required for evaluation of cardiac dysfunction. Presence of gene deletion was associated with higher CT ratio. Older children have been found to have higher heart rates. No other significant correlation with clinical parameters, CPK levels, genotype and steroid therapy was observed. Early detection possibly leads to appropriate treatment thus reducing the morbidity.
UNLABELLED: In about 10% cases of Duchenne muscular dystrophy (DMD), death is due to cardiac dysfunction. The recognition of cardiomyopathy in DMD is thus important. OBJECTIVE: To assess cardiac involvement in DMDpatients by clinical, radiographic, electrocardiographic (ECG) and echocardiographic monitoring and correlate clinical parameters, CPK levels, presence of gene deletion and steroid therapy with cardiac involvement. METHODS: Thirty patients beyond 6 years age, with DMD in advanced stage disease/non-ambulatory were recalled. A detailed clinical evaluation, CPK levels, gene deletion studies were carried out. Cardiac investigations included Chest X-ray, 12 lead ECG and echocardiography. RESULTS: Nineteen patients were non-ambulatory at the time of enrollment. Symptoms or signs suggestive of cardiac dysfunction were seen in only 10%. Gene deletion was identified in 70.3%. Around one-third patients had cardiomegaly. ECG abnormalities were present in 93.3% patients and commonest abnormality was R > 4 mm in V1. Ejection fraction (EF) < 55% was observed in 64.2% and EF < 50% in 17.8%. CONCLUSION:Cardiomyopathy of DMD is characterized by lack of symptoms and few physical signs. Presence of subtle changes like sinus tachycardia may suggest early cardiac involvement. Thus echocardiography is required for evaluation of cardiac dysfunction. Presence of gene deletion was associated with higher CT ratio. Older children have been found to have higher heart rates. No other significant correlation with clinical parameters, CPK levels, genotype and steroid therapy was observed. Early detection possibly leads to appropriate treatment thus reducing the morbidity.
Authors: Ya-Jian Cheng; Di Lang; Shelton D Caruthers; Igor R Efimov; Junjie Chen; Samuel A Wickline Journal: Am J Physiol Heart Circ Physiol Date: 2012-07-09 Impact factor: 4.733
Authors: Christopher Spurney; Reiko Shimizu; Lauren P Morgenroth; Hanna Kolski; Heather Gordish-Dressman; Paula R Clemens Journal: Muscle Nerve Date: 2014-05-14 Impact factor: 3.217
Authors: Christopher F Spurney; Francis M McCaffrey; Avital Cnaan; Lauren P Morgenroth; Sunil J Ghelani; Heather Gordish-Dressman; Adrienne Arrieta; Anne M Connolly; Timothy E Lotze; Craig M McDonald; Robert T Leshner; Paula R Clemens Journal: J Am Soc Echocardiogr Date: 2015-04-21 Impact factor: 5.251
Authors: Christopher F Spurney; Arpana Sali; Alfredo D Guerron; Micaela Iantorno; Qing Yu; Heather Gordish-Dressman; Sree Rayavarapu; Jack van der Meulen; Eric P Hoffman; Kanneboyina Nagaraju Journal: J Cardiovasc Pharmacol Ther Date: 2011-03 Impact factor: 2.457
Authors: Christopher F Spurney; Susan Knoblach; Emidio E Pistilli; Kanneboyina Nagaraju; Gerard R Martin; Eric P Hoffman Journal: Neuromuscul Disord Date: 2008-04-25 Impact factor: 4.296
Authors: Dorothy M Branco; Cordula M Wolf; Megan Sherwood; Peter E Hammer; Peter B Kang; Charles I Berul Journal: J Interv Card Electrophysiol Date: 2007-10-17 Impact factor: 1.900
Authors: Ann R Punnoose; Jonathan R Kaltman; William Pastor; Robert McCarter; Jianping He; Christopher F Spurney Journal: Pediatr Cardiol Date: 2016-06-17 Impact factor: 1.655
Authors: Christopher F Spurney; Alfredo D Guerron; Qing Yu; Arpana Sali; Jack H van der Meulen; Eric P Hoffman; Kanneboyina Nagaraju Journal: BMC Cardiovasc Disord Date: 2011-05-16 Impact factor: 2.298